From: Single-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic review
 |  | Number/total (%) with the outcome with |  |  | |
---|---|---|---|---|---|
Outcome | Number of trials | Rofecoxib 50 mg | Placebo | Relative benefit/risk (95% CI) | NNT/H (95% CI) |
At least 50% pain relief | 5 | (56) | (11) | 4.8 (3.3 to 7.2) | 2.3 (2.0 to 2.6) |
Any adverse event | 2 | (28) | (33) | 0.69 (0.44 to 1.08) | Not calculated |
Nausea | 3 | (7) | (17) | 0.48 (0.26 to 0.88) | -11 (-6 to -40) |
Vomiting | 3 | (4) | (12) | 0.36 (0.16 to 0.79) | -12 (-7 to -46) |